UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
News Apr 04, 2014
UCB has announced that it has launched a major strategic research alliance with Weill-Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need.
This research alliance reflects UCB’s belief that science progresses more rapidly when innovation is fostered by strong partnerships with leading academic partners.
UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill-Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine.
The research programs are aligned with a key strategy of UCB NewMedicines™ to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.
Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said, “No single organization can work alone to translate cutting-edge fundamental scientific research into transformative medicines for people with severe disease. That is why are creating a super network with trusted scientific partners globally, combining knowledge of patient medical need with understanding of disease mechanisms. This strategic research alliance brings together Weill Cornell’s world class academic research with our discovery team with the shared objective of developing medicines that could transform the lives of people with severe diseases.”
“We are thrilled to enter into this strategic alliance with UCB to drive research discoveries made at the bench into the most advanced treatments for patients in the clinic,” Dr. Glimcher said. “UCB has an accomplished track record of developing first-rate treatments and therapies. With complementary expertise and a common mission - to help patients, improve health and save lives - our alliance will demonstrate the power of academic-industry collaboration.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Deadly Mushroom Toxin Helps Fight Cancer?News
The death-cap mushroom has a long history as a tool of murder and suicide, going back to ancient Roman times. While it may seem ill-advised, researchers are eager to synthesize the toxin because studies have shown that it could help fight cancer. Scientists now report how they overcame obstacles to synthesize the death-cap killer compound.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018